These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 1742504

  • 1. Misoprostol prevents NSAID-induced gastroduodenal lesions in patients with osteoarthritis and rheumatoid arthritis.
    Saggioro A, Alvisi V, Blasi A, Dobrilla G, Fioravanti A, Marcolongo R.
    Ital J Gastroenterol; 1991; 23(3):119-23. PubMed ID: 1742504
    [Abstract] [Full Text] [Related]

  • 2. Double blind, placebo controlled trial on the cytoprotective effect of misoprostol in subjects with rheumatoid arthritis, osteoarthritis and seronegative spondarthropathy on NSAIDs.
    Chandrasekaran AN, Sambandam PR, Lal HM, Ramakrishnan S, Porkodi R, Krishnamurthy V, Achutan K.
    J Assoc Physicians India; 1991 Dec; 39(12):919-21. PubMed ID: 1816217
    [Abstract] [Full Text] [Related]

  • 3. Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: a randomized, placebo controlled trial. Arthrotec Osteoarthritis Study Group.
    Bocanegra TS, Weaver AL, Tindall EA, Sikes DH, Ball JA, Wallemark CB, Geis GS, Fort JG.
    J Rheumatol; 1998 Aug; 25(8):1602-11. PubMed ID: 9712107
    [Abstract] [Full Text] [Related]

  • 4. Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAID in patients with rheumatoid arthritis or osteoarthritis, and interim report on prevention by misoprostol of diclofenac associated lesions.
    Geis GS, Stead H, Wallemark CB, Nicholson PA.
    J Rheumatol Suppl; 1991 Mar; 28():11-4. PubMed ID: 1903808
    [Abstract] [Full Text] [Related]

  • 5. Double-blind, double-dummy endoscopic comparison of the mucosal protective effects of misoprostol versus ranitidine on naproxen-induced mucosal injury to the stomach and duodenum in rheumatic patients.
    Bianchi Porro G, Lazzaroni M, Petrillo M.
    Am J Gastroenterol; 1997 Apr; 92(4):663-7. PubMed ID: 9128319
    [Abstract] [Full Text] [Related]

  • 6. [Therapy of non-steroidal antirheumatic drug-induced gastrointestinal lesions with misoprostol].
    Bach GL, Stock KP, Hüdepohl M.
    Z Rheumatol; 1991 Apr; 50(3):175-80. PubMed ID: 1927064
    [Abstract] [Full Text] [Related]

  • 7. [Misoprostol in the prevention of gastric erosions caused by nonsteroidal anti-inflammatory agents].
    Delmas PD, Lambert R, Capron MH.
    Rev Rhum Ed Fr; 1994 Feb; 61(2):126-31. PubMed ID: 7920500
    [Abstract] [Full Text] [Related]

  • 8. Prevention of gastrointestinal complications associated with nonsteroidal antiinflammatory drugs.
    Agrawal NM, Aziz K.
    J Rheumatol Suppl; 1998 May; 51():17-20. PubMed ID: 9596550
    [Abstract] [Full Text] [Related]

  • 9. Prevention and treatment of ulcers induced by nonsteroidal anti-inflammatory drugs.
    Agrawal NM, Dajani EZ.
    J Assoc Acad Minor Phys; 1992 May; 3(4):142-8. PubMed ID: 1392409
    [Abstract] [Full Text] [Related]

  • 10. Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial.
    Simon LS, Hatoum HT, Bittman RM, Archambault WT, Polisson RP.
    Fam Med; 1996 Mar; 28(3):204-10. PubMed ID: 8900554
    [Abstract] [Full Text] [Related]

  • 11. Prevention with sucralfate gel of NSAID-induced gastroduodenal damage in arthritic patients.
    Miglioli M, Bianchi Porro G, Vaira D, Menegatti M, Brunetti G, Petrillo M, Ardizzone S, Frizziero L, Montrone F, Grandinetti G.
    Am J Gastroenterol; 1996 Nov; 91(11):2367-71. PubMed ID: 8931419
    [Abstract] [Full Text] [Related]

  • 12. Prevention and treatment of ulcers induced by nonsteroidal anti-inflammatory drugs: an update.
    Dajani EZ, Agrawal NM.
    J Physiol Pharmacol; 1995 Mar; 46(1):3-16. PubMed ID: 7599335
    [Abstract] [Full Text] [Related]

  • 13. Diclofenac/misoprostol: the European clinical experience.
    McKenna F.
    J Rheumatol Suppl; 1998 May; 51():21-30. PubMed ID: 9596551
    [Abstract] [Full Text] [Related]

  • 14. Healing of NSAID-induced gastric ulcers with a synthetic prostaglandin analog (enprostil).
    Sontag SJ, Schnell TG, Budiman-Mak E, Adelman K, Fleischmann R, Cohen S, Roth SH, Ipe D, Schwartz KE.
    Am J Gastroenterol; 1994 Jul; 89(7):1014-20. PubMed ID: 8017358
    [Abstract] [Full Text] [Related]

  • 15. Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis.
    Goldstein JL, Huang B, Amer F, Christopoulos NG.
    Clin Ther; 2004 Oct; 26(10):1637-43. PubMed ID: 15598480
    [Abstract] [Full Text] [Related]

  • 16. The therapeutic efficacy of misoprostol in peptic ulcer disease.
    Watkinson G, Hopkins A, Akbar FA.
    Postgrad Med J; 1988 Oct; 64 Suppl 1():60-77. PubMed ID: 3138682
    [Abstract] [Full Text] [Related]

  • 17. Nonsteroidal antiinflammatory drugs and the gastrointestinal tract.
    Hirschowitz BI.
    Gastroenterologist; 1994 Sep; 2(3):207-23. PubMed ID: 7987619
    [Abstract] [Full Text] [Related]

  • 18. [Prevention of NSAID induced gastroduodenal ulcers].
    Hansen JM, Bytzer P.
    Ugeskr Laeger; 2001 Oct 29; 163(44):6103-5. PubMed ID: 11715151
    [Abstract] [Full Text] [Related]

  • 19. Misoprostol in the prevention of NSAID-induced gastric ulcer: a multicenter, double-blind, placebo-controlled trial.
    Roth SH.
    J Rheumatol Suppl; 1990 Feb 29; 20():20-4. PubMed ID: 2109073
    [Abstract] [Full Text] [Related]

  • 20. Misoprostol: a prostaglandin for peptic ulcer.
    DiPalma JR.
    Am Fam Physician; 1989 Aug 29; 40(2):217-9. PubMed ID: 2502901
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.